Professor Allyson Pollock
- Email: email@example.com
- Personal Website: http://www.allysonpollock.com
- Address: Institute of Health and Society
Newcastle upon Tyne
Personal Assistant: firstname.lastname@example.org 0191 208 5593
I joined the Institute of Health & Society as Director in January 2017, having formerly been professor of public health research and policy at Queen Mary, University of London. I set up and directed the Centre for International Public Health Policy at the University of Edinburgh from 2005 to 2011 and prior to this I was Head of the Public Health Policy Unit at UCL and Director of Research & Development at UCL Hospitals NHS Trust.
I trained in medicine in Scotland and became a consultant in public health medicine in 1991. My research interests include globalisation; privatisation, marketisation and PFI / PPPs; health services; regulation and trade; pharmaceuticals and clinical trials; and childhood injuries; sport; injury; concussion; head injuries; rugby; long term care; social care.
I undertake research and teaching intended to assist the realisation of these principles of social justice and public health, looking in particular at health systems research, trade, and pharmaceuticals. A strong emphasis is on developing critical analysis through education and research and through translating research findings into policy at the national and international level. The work is interdisciplinary, including epidemiology, law, statistics, economics, accounting, sociology, and anthropology.
Universal access to health care is the primary focus and in particular the means by which local and national systems redistribute resources across society by sharing the risks and costs of ill-health. The work includes the study of public private partnerships in health and long term care, pharmaceuticals, and medical research, and how public health interfaces with trade law and intellectual property agreements.
Local and global issues converge around, for instance, the social and economic aspects of clinical trials, how medicines are accessed, the estimation of the global burden of disease, and evidence underpinning access to medicines policies; the setting of health care priorities through the creation and use of clinical evidence; and the export of managed health care systems.
- Roderick P, Pollock AM. Brexit’s Great Repeal Bill will axe the right to health. BMJ 2017, 357, j2013.
- Casla K, Roderick P, Pollock AM. Disclosure of patients' data to the UK Home Office must stop. BMJ 2017, 358, j3613.
- Pollock AM, White AJ, Kirkwood G. Evidence in support of the call to ban the tackle and harmful contact in school rugby: a response to World Rugby. British Journal of Sports Medicine 2017, 51, 1108-1113.
- Harrington C, Jacobsen FF, Panos J, Pollock AM, Sutaria S, Szebehely M. Marketisation in long term care: a cross country comparison of large for-profit nursing home chains. Health Services Insights 2017, 10, 1178632917710533.
- Pollock AM, Kirkwood G. Tackle and scrum should be banned in school rugby. BMJ 2017.
- Millard C, Kadam A, Mahajan R, Pollock AM, Brhlikova P. The effectiveness of market competition in India’s private pharmacy sector: a study of the availability of brands of six essential medicines in 124 pharmacies in Maharashtra. Journal of Global Health 2017. In Preparation.
- Sutaria S, Roderick P, Pollock AM. The end of the NHS and local government in England as we know them. BMJ 2017. In Press.
- Millard C, Pollock AM, Brhlikova P. Commentary: Evidence versus influence in the WHO procedure for approving essential medicines: misoprostol for maternal health. BMJ 2014, 349, g4823.